Kaufmann S, et al. - An estimation was carried out of the detection rate among three different targeted biopsy approaches of robot-assisted MRI/TRUS fusion (RA-TB), mpMRI in-bore (MRGB), cognitive fusion guidance biopsy (COG-TB) for the identification of prostate cancer (PC) and clinically significant PC (csPC). Data illustrated greater accuracy in detecting PC via in-bore biopsy and MRI/TRUS fusion-guided biopsy than with cognitive fusion as modeled in a newly established normogram.

Methods

• The enrollment consisted of 156 patients with a lesion on mpMRI, carried out in accordance with ESUR guidelines, due to cancer suspicion or on-going cancer suspicion after prior negative prostate biopsy between 2014 and 2016.
• Candidates underwent targeted biopsy with RA-TB, MRGB or COG-TB.
• Rating of all lesions were performed on the basis of PI-RADS v2.
• Experts comparatively scrutinized the detection rates between techniques.
• They formulated models in order to speculate the detection of overall PC and csPC using a 1000 boot-strap sample.

Results

• A total of 73, 45 and 38 patients underwent RA-TB, MRGB or COG-TB, respectively.
• Overall PC was discovered in 39 (52.42%), 23 (51.11%) and 11 (28.95%) (p=0.04) patients of RA-TB, MRGB and COG-TB arm, respectively.
• In terms of the csPC detection, it was revealed in 26 (35.62%),18 (40.0%) and 9 (23.68%) patients of RA-TB, MRGB and COG-TB arm (p=0.27).
• As per the results, model 1 exhibited a link between RA-TB [OR: 10.08 (95% CI 1.95-51.97); p < 0.01] and MRGB [OR: 12.88 (95% CI 2.36-70.25); p < 0.01] with overall PC detection in TB.
• On the other hand, only MRGB correlated with csPC at TB (model 2) [OR: 5.72; (95% CI 1.40-23.35); p < 0.01].
• Findings unveiled that the c-index for model 1 and model 2 was 0.86 and 0.85, respectively.
• No notable complications were reported between the groups.